Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
Si Li,1,* Wei Wei,1,* Yi Jiang,1 Qiuyun Li,1 Qinghua Huang,1 Huawei Yang,1 Jianlun Liu1,2 1Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China; 2Department of General Surgery, Longdong Hospital of Guangxi Medical University, Nanning, Gu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-09-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/comparison-of-the-efficacy-and-survival-analysis-of-neoadjuvant-chemot-peer-reviewed-article-DDDT |
| _version_ | 1818265975135404032 |
|---|---|
| author | Li S Wei W Jiang Y Li Q Huang Q Yang H Liu J |
| author_facet | Li S Wei W Jiang Y Li Q Huang Q Yang H Liu J |
| author_sort | Li S |
| collection | DOAJ |
| description | Si Li,1,* Wei Wei,1,* Yi Jiang,1 Qiuyun Li,1 Qinghua Huang,1 Huawei Yang,1 Jianlun Liu1,2 1Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China; 2Department of General Surgery, Longdong Hospital of Guangxi Medical University, Nanning, Guangxi, China *These authors contributed equally to this work Purpose: The objective of this research was to compare the short- and long-term efficacy of the following four neoadjuvant chemotherapy (NAC) regimens: docetaxel/carboplatin/trastuzumab (TCH), docetaxel/epirubicin/cyclophosphamide (TEC), Xeloda/epirubicin/cyclophosphamide followed by Xeloda/docetaxel (XEC-XT), and 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel (FEC-T) in human epidermal growth factor receptor-2-positive (Her-2-positive) breast cancer. Patients and methods: According to treatment preferences, 139 patients with Her-2-positive breast cancer were divided into the following four groups: 39 patients in the TCH group, 35 patients in the TEC group, 33 patients in the XEC-XT group, and 32 patients in the FEC-T group. The primary end points were disease-free survival (DFS) and 5-year overall survival (5-year OS). The secondary end points were the efficacy and toxicity of NAC. Results: The TCH, TEC, XEC-XT, and FEC-T groups demonstrated overall response rates of 87.1%, 74.3%, 75.8%, and 62.5% (P=0.031), respectively, and pathological complete response rates of 25.6%, 18.2%, 20.0%, and 18.2% (P=0.041), respectively. The DFS rates for the TCH, TEC, XEC-XT, and FEC-T groups were 84.6%, 62.9%, 65.7%, and 46.9% (P=0.01), respectively. The 5-year OS rates for the TCH, TEC, XEC-XT, and FEC-T groups were 87.2%, 69.7%, 71.4%, and 59.4% (P=0.069), respectively. The mean survival time was 59.3 months (TCH group), 53.5 months (TEC group), 55.3 months (XEC-XT group), and 52.4 months (FEC-T group). The difference in survival among the four groups was statistically significant (P=0.04). Conclusion: In four NAC regimens for the treatment of Her-2-positive breast cancer, the TCH group exhibited better DFS and 5-year OS. The TCH regimen significantly enhanced the pathological complete remission rate of NAC with similar side effects compared to the TEC, XEC-XT, and FEC-T regimens. In terms of long-term efficacy, the XEC-XT treatment was superior to the FEC-T and TEC treatment, and there was no significant difference between the FEC-T and TEC groups. Keywords: Her-2-positive breast cancer, neoadjuvant chemotherapy, trastuzumab, efficacy, survival analysis, toxic side effects |
| first_indexed | 2024-12-12T19:59:20Z |
| format | Article |
| id | doaj.art-98ad81b315d1404987f1fd30af1f683a |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-12T19:59:20Z |
| publishDate | 2018-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-98ad81b315d1404987f1fd30af1f683a2022-12-22T00:13:48ZengDove Medical PressDrug Design, Development and Therapy1177-88812018-09-01Volume 123085309340794Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancerLi SWei WJiang YLi QHuang QYang HLiu JSi Li,1,* Wei Wei,1,* Yi Jiang,1 Qiuyun Li,1 Qinghua Huang,1 Huawei Yang,1 Jianlun Liu1,2 1Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China; 2Department of General Surgery, Longdong Hospital of Guangxi Medical University, Nanning, Guangxi, China *These authors contributed equally to this work Purpose: The objective of this research was to compare the short- and long-term efficacy of the following four neoadjuvant chemotherapy (NAC) regimens: docetaxel/carboplatin/trastuzumab (TCH), docetaxel/epirubicin/cyclophosphamide (TEC), Xeloda/epirubicin/cyclophosphamide followed by Xeloda/docetaxel (XEC-XT), and 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel (FEC-T) in human epidermal growth factor receptor-2-positive (Her-2-positive) breast cancer. Patients and methods: According to treatment preferences, 139 patients with Her-2-positive breast cancer were divided into the following four groups: 39 patients in the TCH group, 35 patients in the TEC group, 33 patients in the XEC-XT group, and 32 patients in the FEC-T group. The primary end points were disease-free survival (DFS) and 5-year overall survival (5-year OS). The secondary end points were the efficacy and toxicity of NAC. Results: The TCH, TEC, XEC-XT, and FEC-T groups demonstrated overall response rates of 87.1%, 74.3%, 75.8%, and 62.5% (P=0.031), respectively, and pathological complete response rates of 25.6%, 18.2%, 20.0%, and 18.2% (P=0.041), respectively. The DFS rates for the TCH, TEC, XEC-XT, and FEC-T groups were 84.6%, 62.9%, 65.7%, and 46.9% (P=0.01), respectively. The 5-year OS rates for the TCH, TEC, XEC-XT, and FEC-T groups were 87.2%, 69.7%, 71.4%, and 59.4% (P=0.069), respectively. The mean survival time was 59.3 months (TCH group), 53.5 months (TEC group), 55.3 months (XEC-XT group), and 52.4 months (FEC-T group). The difference in survival among the four groups was statistically significant (P=0.04). Conclusion: In four NAC regimens for the treatment of Her-2-positive breast cancer, the TCH group exhibited better DFS and 5-year OS. The TCH regimen significantly enhanced the pathological complete remission rate of NAC with similar side effects compared to the TEC, XEC-XT, and FEC-T regimens. In terms of long-term efficacy, the XEC-XT treatment was superior to the FEC-T and TEC treatment, and there was no significant difference between the FEC-T and TEC groups. Keywords: Her-2-positive breast cancer, neoadjuvant chemotherapy, trastuzumab, efficacy, survival analysis, toxic side effectshttps://www.dovepress.com/comparison-of-the-efficacy-and-survival-analysis-of-neoadjuvant-chemot-peer-reviewed-article-DDDTNeoadjuvant chemotherapy/Her-2 positive breast cancer |
| spellingShingle | Li S Wei W Jiang Y Li Q Huang Q Yang H Liu J Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer Drug Design, Development and Therapy Neoadjuvant chemotherapy/Her-2 positive breast cancer |
| title | Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer |
| title_full | Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer |
| title_fullStr | Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer |
| title_full_unstemmed | Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer |
| title_short | Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer |
| title_sort | comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for her 2 positive breast cancer |
| topic | Neoadjuvant chemotherapy/Her-2 positive breast cancer |
| url | https://www.dovepress.com/comparison-of-the-efficacy-and-survival-analysis-of-neoadjuvant-chemot-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT lis comparisonoftheefficacyandsurvivalanalysisofneoadjuvantchemotherapyforher2positivebreastcancer AT weiw comparisonoftheefficacyandsurvivalanalysisofneoadjuvantchemotherapyforher2positivebreastcancer AT jiangy comparisonoftheefficacyandsurvivalanalysisofneoadjuvantchemotherapyforher2positivebreastcancer AT liq comparisonoftheefficacyandsurvivalanalysisofneoadjuvantchemotherapyforher2positivebreastcancer AT huangq comparisonoftheefficacyandsurvivalanalysisofneoadjuvantchemotherapyforher2positivebreastcancer AT yangh comparisonoftheefficacyandsurvivalanalysisofneoadjuvantchemotherapyforher2positivebreastcancer AT liuj comparisonoftheefficacyandsurvivalanalysisofneoadjuvantchemotherapyforher2positivebreastcancer |